Balyasny Asset Management LLC Intellia Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

$58 Billion
Q3 2024

A detailed history of Balyasny Asset Management LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 749,861 shares of NTLA stock, worth $9.13 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

749,861

Previous 347,483 115.8%

Holding current value

$9.13 Million

Previous $7.78 Million 98.16%

% of portfolio

0.03%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $7.93 Million - $11 Million	402,378 Added 115.8%	749,861 $15.4 Million
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $3.18 Million - $4.33 Million	158,982 Added 84.34%	347,483 $7.78 Million
Q1 2024 May 13, 2024	BUY	$23.82 - $32.8 $4.49 Million - $6.18 Million	188,501 New	188,501 $5.19 Million
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $1.29 Million - $2.44 Million	-38,927 Reduced 98.08%	762 $26,000
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $2.14 Million - $2.85 Million	39,689 New	39,689 $2.22 Million
Q2 2021 Aug 16, 2021	SELL	$60.88 - $161.91 $2.36 Million - $6.27 Million	-38,720 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$46.59 - $83.68 $2.07 Million - $3.72 Million	-44,473 Reduced 53.46%	38,720 $3.11 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $1.57 Million - $5.29 Million	83,193 New	83,193 $4.53 Million
Q3 2019 Nov 14, 2019	SELL	$13.07 - $18.51 $749,185 - $1.06 Million	-57,321 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$13.88 - $18.41 $162,049 - $214,936	11,675 Added 25.58%	57,321 $938,000
Q1 2019 May 15, 2019	SELL	$12.79 - $17.62 $16,179 - $22,289	-1,265 Reduced 2.7%	45,646 $780,000
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $534,316 - $1.27 Million	46,911 New	46,911 $640,000

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Intellia Therapeutics, Inc. Transaction History